Trial · NCT01506596
Study of Pazopanib in the Treatment of Surgically Unresectable or Metastatic Liposarcoma
NCT01506596, Phase 2, Completed, Vector Oncology; results first posted 2016-05-25
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Study of Pazopanib in the Treatment of Surgically Unresectable or Metastatic Liposarcoma. Trials, record NCT01506596. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT01506596
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Study of Pazopanib in the Treatment of Surgically Unresectable or Metastatic Liposarcoma
- NCT number
- NCT01506596
- Status
- Completed
- Phases
- Phase 2
- Enrollment
- 42 participants, actual
- Lead sponsor
- Vector Oncology
- Conditions
- Liposarcoma, Surgically Unresectable Liposarcoma, Metastatic Liposarcoma
- Interventions
- pazopanib
- First posted
- 2012-01-10
- Last updated
- 2017-02-15
- Results first posted
- 2016-05-25
Source ClinicalTrials.gov
Registered outcomes5
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | 12-week Progression Free Rate | Assessed after 12 weeks of study treatment | Progression will be as defined per Response Evaluation Criteria In Solid Tumors (RECIST) guidelines version 1.1. Subjects who remain under observation and progression free at 12 weeks will be defined as treatment successes. Subjects who progress per RECIST by 12 weeks or who drop out without evidence of progression prior to 12 weeks will be defined as treatment failures.Progression is defined using Response Evaluation Criteria in Solid Tumors (RECIST v1.1), as a \>=20% increase in the sum of diameters of target lesions, or a measurable increase in a non-target lesion, or the appearance of \>=1 new lesion. |
| Secondary | Progression Free Survival (PFS) | Date of Consent until progression or death, up to 27 months | PFS was measured from date of consent until the subject experiences disease progression (assessed approximately every 12 weeks) or death, whichever came first, up to 27 months. Repeat radiologic imaging will be conducted after every 3 cycles of treatment (approximately every 12 weeks) to evaluate disease status per RECIST v1.1. Subjects who discontinue study treatment for reasons other than disease progression will continue to have their disease status reported every 3 months post end of treatment up to 27 months. |
| Secondary | Best Overall Response | Date of consent until end of study treatment, up to 32 months | Best overall response is defined as the best response across all time points. Repeat radiologic imaging was conducted after every 3 cycles of treatment (approximately every 12 weeks). Response was evaluated using RECIST v1.1 guidelines, where complete response (CR) is the disappearance of all target and non-target lesions; partial response (PR) is \>=30% decrease in the sum of diameters of target lesions; progressive disease (PD) is \>=20% increase in the sum of diameters of target lesions, or a measurable increase in a non-target lesion, or the appearance of \>=1 new lesion; stable disease (SD) is neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD. |
| Secondary | Duration of Response | Measure of the amount of time that the criteria for response per RECIST are first met until disease progression | Response is defined as Complete Response (CR) or Partial Response (PR) per RECIST v1.1. Repeat radiologic imaging will be conducted after every 3 cycles of treatment (approximately every 12 weeks) to evaluate disease status per RECIST v1.1. Confirmation of CR or PR is required by repeat scans that should be performed 4 weeks after the criteria for response are first met. |
| Secondary | Overall Survival (OS) | Date of Consent until death, up to 32 months | OS was measured from date of consent until time of death from any cause, up to 32 months. |
Source ClinicalTrials.gov
Outcomes5
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | 12-week Progression Free Rate | Assessed after 12 weeks of study treatment | percentage of participants | NUMBER | |
| SECONDARY | Progression Free Survival (PFS) | Date of Consent until progression or death, up to 27 months | months | MEDIAN | |
| SECONDARY | Best Overall Response | Date of consent until end of study treatment, up to 32 months | percentage of participants | NUMBER | |
| SECONDARY | Duration of Response | Measure of the amount of time that the criteria for response per RECIST are first met until disease progression | Since so few patients experienced a response, the pre-specified endpoint of duration of response was not analyzed. | ||
| SECONDARY | Overall Survival (OS) | Date of Consent until death, up to 32 months | months | MEDIAN |
Source ClinicalTrials.gov
Results by group8
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| 12-week Progression Free Rate | Pazopanib | 68.29 | 95% Confidence Interval 51.91 to 81.92 | percentage of participants | |
| Progression Free Survival (PFS) | Pazopanib | 4.44 | 95% Confidence Interval 3.2 to 6.5 | months | |
| Best Overall Response | Pazopanib | Complete response | 0 | percentage of participants | |
| Best Overall Response | Pazopanib | Partial Response | 2.4 | percentage of participants | |
| Best Overall Response | Pazopanib | Stable Disease | 41.5 | percentage of participants | |
| Best Overall Response | Pazopanib | Progressive Disease | 43.9 | percentage of participants | |
| Best Overall Response | Pazopanib | Inevaluable | 12.2 | percentage of participants | |
| Overall Survival (OS) | Pazopanib | 12.62 | 95% Confidence Interval 8.5 to 16.2 | months |
Source ClinicalTrials.gov
Participant flow3
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Pazopanib | 42 | |
| Overall Study | COMPLETED | Pazopanib | 41 | |
| Overall Study | NOT COMPLETED | Pazopanib | 1 |
Source ClinicalTrials.gov
Adverse events193
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Anaemia | Blood and lymphatic system disorders | Pazopanib | 7 | 41 | |
| other | Leukopenia | Blood and lymphatic system disorders | Pazopanib | 1 | 41 | |
| other | Neutropenia | Blood and lymphatic system disorders | Pazopanib | 1 | 41 | |
| other | Thrombocytopenia | Blood and lymphatic system disorders | Pazopanib | 2 | 41 | |
| other | Atrial Fibrillation | Cardiac disorders | Pazopanib | 1 | 41 | |
| other | Cardiac Failure Congestive | Cardiac disorders | Pazopanib | 1 | 41 | |
| other | Palpitations | Cardiac disorders | Pazopanib | 1 | 41 | |
| other | Sinus Tachycardia | Cardiac disorders | Pazopanib | 1 | 41 | |
| other | Tinnitus | Ear and labyrinth disorders | Pazopanib | 1 | 41 | |
| other | Vertigo | Ear and labyrinth disorders | Pazopanib | 1 | 41 |
1 to 10 of 193Source ClinicalTrials.gov
See all 193 adverse eventsAdverse event totals3
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Pazopanib | ||
| Total, other adverse events | Pazopanib | 39 | 41 |
| Total, serious adverse events | Pazopanib | 17 | 41 |
Source ClinicalTrials.gov
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT01506596
GET https://conductscience.org/api/trials/v1/NCT01506596/events?page=2